Monte Rosa Therapeutics
在场
高管
查看带有其 17 名主要高管的组织结构图
Monte Rosa Therapeutics 搜索最多的简介
高管在Monte Rosa Therapeutics变化
- Sharon Townson 曾任 Chief Technology Officer, 现升职为 Chief Scientific Officer (新闻发布的2024五月30号).
- Phil Nickson 曾任 General Counsel, 现升职为 Chief Business and Legal Officer (新闻发布的2024五月30号).
- Owen Wallace, Chief Scientific Officer, 已经离开公司 (新闻发布的2024五月3号).
创建提醒
跟踪 Monte Rosa Therapeutics 的高管变动
生物技术
Monte Rosa Therapeutics 拥有 2,317 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- Evommune 刚刚宣布为 115 筹款数百万美元。 (公布2024十一月4号).
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
生物技术 行业的其他推荐联系人
消息
Monte Rosa Therapeutics 的最新新闻稿
- Monte Rosa Therapeutics Announces Global License Agreement with Novartis to Advance T and B Cell-modulating VAV1-directed Molecular Glue Degraders - Monte Rosa Therapeutics
- Monte Rosa Therapeutics Presents Preclinical Data at the 36th EORTC-NCI-AACR Symposium on the Potential of its Cyclin E1-directed Molecular Glue Degraders for the Treatment of CCNE1-Amplified Solid Tumors - Monte Rosa Therapeutics
- Monte Rosa Therapeutics - News
- Monte Rosa Therapeutics Announces First Participants Dosed in MRT-6160 Phase 1 Study | Monte Rosa Therapeutics
- Monte Rosa Therapeutics - News
- Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences | Monte Rosa Therapeutics
- Newsroom - Monte Rosa Therapeutics
- Monte Rosa Therapeutics Announces $95 Million Series C Financing to Accelerate Next-generation Protein Degradation Platform | Business Wire
- Monte Rosa Therapeutics Strengthens Leadership with Key Executive and Board Appointments | Business Wire
- Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences | Business Wire
- View more press releases Close
通过电子邮件
